ArticleActa diabetologica2025

Dapagliflozin ameliorates metabolic and hepatic outcomes in a mouse model of metabolic dysfunction-associated steatotic liver disease and diabetes.

Xiaoya SunPubMed ↗Publisher ↗

No numbers read from the abstract.